JoyceFuLiuMD

Oncology • Boston, MA

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Liu's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-5269

Fax+1 617-632-3479
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Harvard Medical SchoolClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2004 - 2025
VT State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
Active, not recruiting
Phase 1, Phase 2
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
AO-176 in Multiple Solid Tumor Malignancies Start of enrollment: 2019 Feb 04
Completed
Phase 1, Phase 2
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Start of enrollment: 2018 Oct 22
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Start of enrollment: 2016 Nov 10
Active, not recruiting
Phase 2
Roles: Principal Investigator
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Feb 25
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Start of enrollment: 2023 Sep 14
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Start of enrollment: 2023 Nov 14
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Azenosertib in Uterine Serous Carcinoma: Biomarker Study Start of enrollment: 2024 Sep 01
Not yet recruiting
Phase 2
Roles: Sponsor-Investigator, Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.
Xiong, N., Sawyer, H., Polak, M., Needham, H., Geddes, M., Koppermann, L., Shea, M., Castro, C., Cheng, S., Konstantinopoulos, P., Krasner, C., Liu, J., Matulonis, U.,...> ;Gynecologic Oncology Reports. 2024 Apr 1
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.
Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.
St Laurent, J., Liu, J., Quade, B., Davis, M., Abel, M.> ;Gynecologic Oncology Reports. 2024 Feb 1
Treatment Approaches for Platinum-Resistant Ovarian Cancer.
Jessica St Laurent, Joyce F Liu> ;Journal of Clinical Oncology. 2024 Jan 10
1 citations
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Alexi A Wright, Hanneke Poort, Anna Tavormina, Sarah J Schmiege, Ursula A Matulonis, Susana M Campos, Joyce F Liu, Elizabeth T Slivjak, Anna L Gilmour, Julia M Salinge...> ;Gynecologic Oncology. 2023 Oct 1
One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit all.
Jung-Min Lee, Joyce F Liu> ;Cancer. 2023 Jun 15
16 citations
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Kolin, D., Kolin, D., Panagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, Carolyn Krasner, Susana Campos, David L Kolin, Joyce F Liu, Neil Horowitz, Alexi A W...> ;Journal of Clinical Oncology. 2023 Jan 20
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents.
Elizabeth K Lee, Joyce F Liu> ;Cancer Treatment and Research. 2023 Jan 1
15 citations
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Liya Ding, Qiwei Wang, Antons Martincuks, Michael J Kearns, Tao Jiang, Ziying Lin, Xin Cheng, Changli Qian, Shaozhen Xie, Hye-Jung Kim, Inga-Maria Launonen, Anniina Fä...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed ...
Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Carolyn Krasner, Lee Hang, Corrine Zarwan, William Barry, Tina Colella, Christen Whalen, Mel...> ;International Journal of Clinical Oncology. 2022 Dec 1
103 citations
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Lear...> ;Journal of Clinical Oncology. 2023 Jan 20
11 citations
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Kelsey McQueen, Geoffrey ...> ;Cancer Research. 2022 Oct 17
10 citations
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.
Min Liu, Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea, Isabel Carulli, Teddy Huang, Shuqiang Li, Su-Chun Cheng, Phuong Le, Laura Frackie...> ;Clinical Cancer Research. 2022 Aug 2
24 citations
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Jung-Min Lee, Richard G Moore, Sharad Ghamande, Min S Park, John P Diaz, Julia Chapman, James Kendrick, Brian M Slomovitz, Krishnansu S Tewari, Elizabeth S Lowe, Tsvet...> ;Clinical Cancer Research. 2022 Oct 3
12 citations
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Panagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, Carolyn Krasner, Neil Horowitz, Susana Campos, Alexi A Wright, Joyce F Liu, Meghan Shea, Oladapo Yeku, C...> ;JAMA Oncology. 2022 Sep 1
11 citations
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.
Rebecca L Porter, Siyu Sun, Micayla N Flores, Emily Berzolla, Eunae You, Ildiko E Phillips, Neelima Kc, Niyati Desai, Eric C Tai, Annamaria Szabolcs, Evan R Lang, Amay...> ;The Journal of Clinical Investigation. 2022 Aug 15
15 citations
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
16 citations
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, Madeline Polak, Andrea E Wahner-Hendrickson, S Percy Ivy, Brittany Bowes, Hannah Sawyer, Patrice Basada...> ;British Journal of Cancer. 2022 Apr 1
8 citations
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Elizabeth H Stover, Niya Xiong, Andrea P Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, Russell R Broaddus, Vicky Makker, Ronny Drapkin, Joyce F Liu, Neil S H...> ;Gynecologic Oncology Reports. 2022 Apr 1
35 citations
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III T...
Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, Elizabeth M Swisher, David Cella, William P Tew, Noelle G Cloven, Carolyn Y Muller, David P...> ;Journal of Clinical Oncology. 2022 Jul 1
13 citations
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
Joyce F. Liu, Amit M. Oza, Nicoletta Colombo, Ana Oaknin> ;International Journal of Gynecological Cancer. 2021 Oct 29
17 citations
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Joyce F. Liu, Howard A. Burris, Judy S. Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric ...> ;Gynecologic Oncology. 2021 Oct 6
27 citations
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A. Konstantinopoulos, Alexandre André B.A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L...> ;Nature Communications. 2021 Sep 22
12 citations
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Katherine Fuh, Michael A. Bookman, Joyce F. Liu, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Bradley J. Monk, Randy Anderson, Gail McIntyre, Reshma A. Rangw...> ;Gynecologic Oncology. 2021 Aug 30
16 citations
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen N. Moore, Giovanni Scambia, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourle...> ;Gynecologic Oncology. 2021 Aug 2
Join now to see all

Lectures

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017
Join now to see all